Genmab — December 2024
-
TECVAYLI
(teclistamab-cqyv) demonstrates potential as frontline combination therapy for patients with newly diagnosed multiple myeloma https://innovativemedicine.jnj.com/our-innovation/focus-areas/oncology/tecvayli-teclistamab-cqyv-demonstrates-potential-as-frontline-combination-therapy-for-patients-with-newly-diagnosed-multiple-myeloma -
E L..Thank you from the bottom of my heart for your daily tireless distribution of big and small news from Genmab and the pipeline.
-
-
-
Servicemeddelelse: Efter serverskiftet i weekenden kører vores newsfeed desværre ikke pt. Vi arbejder på at få løst problemet.
-
Tror godt at JNJ udnytter optionen, hvis erzo differentierer sig fra faspro. Der er usikkerhed til prisen de kan forlange for faspro efter patentudløb på dara. Men kommer det prispres ikke fra US m.v. så vil der ikke blive solgt meget erzo før faspros patent udløber.
-
Royalty på tec og tal er low single digit. Nærmere 4%. Tec og tal indeholder kun et molekyle fra Genmab.Det
er kun rybrevant der har high single digit, da begge molekyler kommer fra Genmab. -
Det er nu "a mid-single digit royalty"
-
"mid single digit"
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind